Comment on “management and Outcome of Local Regrowths in a Watch-and-wait Prospective Cohort for Complete Responses in Rectal Cancer”

Zihan Han,Zhaoya Gao,Jiajia Chen,Qingkun Gao,Fuming Lei,Jin Gu

DOI: https://doi.org/10.1097/as9.0000000000000156

2022-01-01

Annals of Surgery Open

Abstract:To the Editor: We read the article published in Annals of Surgery , titled “Management and Outcome of Local Regrowths in a Watch-and-wait Prospective Cohort for Complete Responses in Rectal Cancer.” 1 Beets et al explored the surgical treatment and prognosis of patients, who achieved a complete or near-complete response after neoadjuvant chemoradiotherapy for rectal cancer. We were interested in this article because we conducted a similar study. 2 Here, we discuss some of their findings based on our experience and the results of our study. First, in terms of study enrollment, the researchers recruited both patients with a complete response (cCR) and near-complete response (near-cCR). However, we believe that there is a significant difference between the diagnoses of cCR and near-cCR. In this article, the diagnosis of near-cCR lymph nodes is described as “obvious downstaging of lymph nodes but remaining node(s) ≥5 mm,” which is obviously different from the diagnosis criteria for cCR patients, and this difference may have a direct impact on tumor recurrence and metastasis rates. Moreover, the researchers did not provide the number of cases in the near-cCR and cCR groups, nor did they analyze these patients in subgroups. The absence of such key data may lead researchers and readers to misunderstand the conclusions of this study. Second, more than half of the patients (16/26) with tumor stage ≥ ypT2 underwent local excision, which is questionable. Two clinical trials, ACOSOG Z6041 3 and GRECCAR 2, 4 concluded that local excision was feasible for patients with small T2/T3 (base-line tumor < 4 cm) low-third rectal cancer with a good clinical response after chemoradiotherapy